Caricamento...
Enfortumab Vedotin in urothelial cancer
The treatment landscape for metastatic urothelial cancer (mUC) beyond first-line platinum-based chemotherapy has changed significantly over the last 5 years with the recent approvals of the immune checkpoint inhibitors (ICIs), fibroblast growth factor receptor (FGFR) inhibitors and most recently Enf...
Salvato in:
| Pubblicato in: | Ther Adv Urol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7780177/ https://ncbi.nlm.nih.gov/pubmed/33447264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287220980192 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|